Mark J. Willette, Ph.D. - Publications
Affiliations: | 2010 | Microbiology, Immunology and Cancer Biology | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Immunology, OncologyYear | Citation | Score | |||
---|---|---|---|---|---|
2017 | Katerndahl CD, Heltemes-Harris LM, Willette MJ, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KA, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, et al. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nature Immunology. PMID 28369050 DOI: 10.1038/Ni.3716 | 0.526 | |||
2011 | Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, Thomas DA, Koeuth T, Baechler EC, Kornblau SM, Farrar MA. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. The Journal of Experimental Medicine. 208: 1135-49. PMID 21606506 DOI: 10.1084/Jem.20101947 | 0.516 | |||
2011 | Heltemes-Harris LM, Willette MJ, Vang KB, Farrar MA. The role of STAT5 in the development, function, and transformation of B and T lymphocytes. Annals of the New York Academy of Sciences. 1217: 18-31. PMID 21276004 DOI: 10.1111/J.1749-6632.2010.05907.X | 0.592 | |||
Show low-probability matches. |